WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
WuXi Biologics (2269.HK) has launched EffiX™, a proprietary E. coli expression system designed for high-yield production of recombinant proteins and plasmid DNA. The platform achieves exceptional yields of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.
The technology addresses growing market demand for microbial-derived products including antibody fragments, nanobodies, enzymes, cytokines, antigens, polypeptides, and plasmid DNA. EffiX™ offers streamlined processes from research through commercial manufacturing, providing a comprehensive Chemistry, Manufacturing, and Controls (CMC) strategy for biotherapeutics development.
The platform is part of WuXi Biologics' integrated technology ecosystem, supporting early-stage research, CMC development, and GMP manufacturing for next-generation therapies.
WuXi Biologics (2269.HK) ha lanciato EffiX™, un sistema di espressione proprietario di E. coli progettato per la produzione ad alto rendimento di proteine ricombinanti e DNA plasmidico. La piattaforma raggiunge rendimenti eccezionali di oltre 15 g/L per proteine ricombinanti non mAb e oltre 1 g/L per DNA plasmidico.
Questa tecnologia soddisfa la crescente domanda di mercato per prodotti derivati da microrganismi, inclusi frammenti di anticorpi, nanocorpi, enzimi, citochine, antigeni, polipeptidi e DNA plasmidico. EffiX™ offre processi semplificati dalla ricerca fino alla produzione commerciale, fornendo una strategia completa di Chimica, Produzione e Controlli (CMC) per lo sviluppo di bioterapeutici.
La piattaforma fa parte dell'ecosistema tecnologico integrato di WuXi Biologics, supportando la ricerca nelle fasi iniziali, lo sviluppo CMC e la produzione GMP per terapie di nuova generazione.
WuXi Biologics (2269.HK) ha lanzado EffiX™, un sistema de expresión propietario de E. coli diseñado para la producción de alto rendimiento de proteínas recombinantes y ADN plasmídico. La plataforma logra rendimientos excepcionales de más de 15 g/L para proteínas recombinantes no mAb y más de 1 g/L para ADN plasmídico.
La tecnología aborda la creciente demanda del mercado de productos derivados de microorganismos, incluidos fragmentos de anticuerpos, nanocuerpos, enzimas, citoquinas, antígenos, polipéptidos y ADN plasmídico. EffiX™ ofrece procesos simplificados desde la investigación hasta la fabricación comercial, proporcionando una estrategia integral de Química, Fabricación y Controles (CMC) para el desarrollo de bioterapéuticos.
La plataforma es parte del ecosistema tecnológico integrado de WuXi Biologics, apoyando la investigación en etapas tempranas, el desarrollo CMC y la fabricación GMP para terapias de próxima generación.
우시 바이오로직스 (2269.HK)는 EffiX™를 출시했습니다. 이는 재조합 단백질과 플라스미드 DNA의 고수익 생산을 위해 설계된 독점 E. coli 발현 시스템입니다. 이 플랫폼은 비 mAb 재조합 단백질에 대해 15 g/L 이상의 예외적인 수익과 플라스미드 DNA에 대해 1 g/L 이상의 수익을 달성합니다.
이 기술은 항체 조각, 나노바디, 효소, 사이토카인, 항원, 폴리펩타이드 및 플라스미드 DNA를 포함한 미생물 유래 제품에 대한 증가하는 시장 수요를 해결합니다. EffiX™는 연구에서 상업적 제조에 이르는 간소화된 프로세스를 제공하며, 생물치료제 개발을 위한 종합적인 화학, 제조 및 품질 관리(CMC) 전략을 제공합니다.
이 플랫폼은 우시 바이오로직스의 통합 기술 생태계의 일환으로, 초기 연구, CMC 개발 및 차세대 치료를 위한 GMP 제조를 지원합니다.
WuXi Biologics (2269.HK) a lancé EffiX™, un système d'expression propriétaire d'E. coli conçu pour la production à haut rendement de protéines recombinantes et d'ADN plasmidique. La plateforme atteint des rendements exceptionnels de plus de 15 g/L pour les protéines recombinantes non mAb et plus de 1 g/L pour l'ADN plasmidique.
Cette technologie répond à la demande croissante du marché pour des produits dérivés de microorganismes, y compris des fragments d'anticorps, des nanocorps, des enzymes, des cytokines, des antigènes, des polypeptides et de l'ADN plasmidique. EffiX™ offre des processus simplifiés de la recherche à la fabrication commerciale, fournissant une stratégie complète de chimie, fabrication et contrôles (CMC) pour le développement de biothérapeutiques.
La plateforme fait partie de l'écosystème technologique intégré de WuXi Biologics, soutenant la recherche en phase précoce, le développement CMC et la fabrication GMP pour les thérapies de nouvelle génération.
WuXi Biologics (2269.HK) hat EffiX™ eingeführt, ein proprietäres E. coli-Expressionssystem, das für die hochgradige Produktion von rekombinanten Proteinen und Plasmid-DNA konzipiert ist. Die Plattform erreicht außergewöhnliche Erträge von über 15 g/L für nicht-mAb rekombinante Proteine und über 1 g/L für Plasmid-DNA.
Die Technologie adressiert die wachsende Marktnachfrage nach mikrobiell abgeleiteten Produkten, einschließlich Antikörperfragmenten, Nanobodies, Enzymen, Zytokinen, Antigenen, Polypeptiden und Plasmid-DNA. EffiX™ bietet optimierte Prozesse von der Forschung bis zur kommerziellen Herstellung und stellt eine umfassende Strategie für Chemie, Herstellung und Kontrollen (CMC) für die Entwicklung von Biotherapeutika bereit.
Die Plattform ist Teil des integrierten Technologie-Ökosystems von WuXi Biologics, das die Forschung in frühen Phasen, die CMC-Entwicklung und die GMP-Herstellung für Therapien der nächsten Generation unterstützt.
- Achieves high yields: >15 g/L for non-mAb proteins, >1 g/L for plasmid DNA
- Expands capabilities in growing microbial-derived products market
- Offers comprehensive solution from research to commercial manufacturing
- None.
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe
- EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA
The global market for microbial-derived products and intermediates is expanding rapidly, driven by increasing demand for smaller complex biomolecules — such as antibody fragments, nanobodies, enzymes, cytokines, various antigens, polypeptides, and plasmid DNA (pDNA) — all of which present significant opportunities for the development of next-generation therapies. To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with high yield, consistent quality, as well as superior stability and scalability. The EffiX™ platform achieves titers exceeding 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.
With streamlined processes tailored to accommodate a diverse range of project requirements from research through commercial manufacturing, the EffiX™ platform accelerates the advancement of innovative biotherapeutics for global partners by offering a comprehensive and cost-effective Chemistry, Manufacturing, and Controls (CMC) strategy.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients exceptional productivity and product quality, along with scalability and flexibility at every stage of development. WuXi Biologics' continual launching of new technology platforms stems from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to accelerate the delivery of more high-quality and affordable biologics to patients worldwide."
The EffiX™ platform is an integral component of a broader integrated technology platform at WuXi Biologics, which is predicated on microbial expression systems. This comprehensive platform encompasses early-stage research, CMC development, and GMP manufacturing, facilitating faster, more efficient, and cost-effective manufacturing processes for various modalities in the realm of next-generation therapies.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-launches-effix-microbial-expression-platform-to-boost-recombinant-protein-and-plasmid-dna-production-302389868.html
SOURCE WuXi Biologics
FAQ
What production yields can WuXi Biologics' EffiX platform achieve for WXXWY shareholders?
What types of biomolecules can be produced using WuXi Biologics' new EffiX platform?
How does the EffiX platform benefit WuXi Biologics' manufacturing capabilities?
What market opportunity is WuXi Biologics targeting with the EffiX platform launch?
